相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis
Luisa Diomede et al.
BLOOD (2014)
Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach
Giovanni Palladini et al.
HAEMATOLOGICA (2014)
Update on treatment of light chain amyloidosis
Shameem Mahmood et al.
HAEMATOLOGICA (2014)
New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)
E. M. Ocio et al.
LEUKEMIA (2014)
Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity
Jian Guan et al.
BASIC RESEARCH IN CARDIOLOGY (2013)
Systemic light chain amyloidosis: an update for treating physicians
Giampaolo Merlini et al.
BLOOD (2013)
A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis
Ashutosh D. Wechalekar et al.
BLOOD (2013)
Light chain amyloidosis: the heart of the problem
Giampaolo Merlini et al.
HAEMATOLOGICA (2013)
Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis
H. Landau et al.
LEUKEMIA (2013)
Nutritional status independently affects quality of life of patients with systemic immunoglobulin light-chain (AL) amyloidosis
Riccardo Caccialanza et al.
ANNALS OF HEMATOLOGY (2012)
Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue
Francesca Brambilla et al.
BLOOD (2012)
Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis
Joseph R. Mikhael et al.
BLOOD (2012)
Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival
Christopher P. Venner et al.
BLOOD (2012)
New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes
Giovanni Palladini et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements
Shaji Kumar et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis
R. L. Comenzo et al.
LEUKEMIA (2012)
Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study
Donna E. Reece et al.
BLOOD (2011)
Transplantation vs. conventional-dose therapy for amyloidosis
Giovanni Palladini et al.
CURRENT OPINION IN ONCOLOGY (2011)
Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects
S. W. Dubrey et al.
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE (2011)
Introducing the New Editor of Amyloid: the Journal of Protein Folding Disorders, Per Westermark, MD, Ph.D.
Martha Skinner et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2010)
Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement
Sascha Dietrich et al.
BLOOD (2010)
Bortezomib With or Without Dexamethasone in Primary Systemic (Light Chain) Amyloidosis
Efstathios Kastritis et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Review of clinical trials conducted in Waldenstrom macroglobulinemia and recommendations for reporting clinical trial responses in these patients
Meghan Rourke et al.
LEUKEMIA & LYMPHOMA (2010)
The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition
Giada Bianchi et al.
BLOOD (2009)
Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study
Donna E. Reece et al.
BLOOD (2009)
Identification of Amyloidogenic Light Chains Requires the Combination of Serum-Free Light Chain Assay with Immunofixation of Serum and Urine
Giovanni Palladini et al.
CLINICAL CHEMISTRY (2009)
Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease
Ashutosh D. Wechalekar et al.
HAEMATOLOGICA (2008)
Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone
Efstathios Kastritis et al.
HAEMATOLOGICA (2007)
High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis
Arnaud Jaccard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis
Giovanni Palladini et al.
BLOOD (2007)
Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL
Giovanni Palladini et al.
BLOOD (2006)
Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation
G Palladini et al.
BLOOD (2004)
Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis
A Dispenzieri et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628
MV Dhodapkar et al.
BLOOD (2004)
Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis
G Palladini et al.
CIRCULATION (2003)
Holter monitoring in AL amyloidosis:: Prognostic implications
G Palladini et al.
PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY (2001)
A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis
G Palladini et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
分享论文
